In an article published in the journal JAMA the authors compared targeted prostate biopsy compared to standard extended sextant biopsies in 1003 men suspected to have prostate cancer. MRI/USS fusion biopsy detected 30% more high risk prostate cancers than standard biopsy. An additional benefit was that the targeted technique picked up17% fewer low risk cancers. When radical prostatectomy specimens from 170 men were examined, targeted biopsies had a higher PPV for intermediate and high risk cancers than standard biopsies.